Tirzepatide vs. Semaglutide: A Clinical Comparison
This comparison is not as simple as ‘tirzepatide wins, use tirzepatide.’ The full picture is more nuanced.
- In the first head-to-head trial (SURMOUNT-5, NEJM 2025), tirzepatide produced 20.2% average weight loss vs. 13.7% with semaglutide over 72 weeks — about 50 lbs vs. 33 lbs.
- In our clinical experience at Rivas, tirzepatide patients lose weight faster, plateau less often, and are less likely to stop treatment due to side effects.
- The two drugs have distinct GI profiles: semaglutide tends toward nausea and constipation; tirzepatide more commonly causes diarrhea, with much less nausea.
- We often start patients on semaglutide for cost reasons — it works well and some people tolerate it perfectly. Tirzepatide is not automatically the right first choice.
- Both are available at Rivas. Which is right for you is determined at your clinical evaluation.
A note on perspective and our clinical model: I’m Eli Luft, PA-C, COO of Rivas Medical Weight Loss. I’ve been treating patients with both semaglutide and tirzepatide across our 15 Maryland and Virginia locations since both medications became available. What follows is a combination of what the clinical evidence shows and what I actually observe in practice — which don’t always tell the same story.
On our model: At Rivas, the large majority of our GLP-1 patients use compounded semaglutide or compounded tirzepatide, drawn from vials and administered in-office by their provider at each visit. Compounded medications are not FDA-approved and are not the same as brand-name products. The clinical observations I describe — plateau patterns, side effect profiles, speed of response — reflect that vial-based model. We also offer brand-name Wegovy and Zepbound when clinically appropriate, but our day-to-day experience is primarily with compounded medications.
The state of play in 2026
For years, clinicians compared tirzepatide and semaglutide across separate trials with different patient populations, different endpoints, and different study designs. That made direct comparisons imprecise at best and misleading at worst. Then in May 2025, the first direct head-to-head trial — SURMOUNT-5 — was published in the New England Journal of Medicine, putting the two medications head-to-head in the same patients, at the same time, under the same conditions.
The result was not particularly close. Tirzepatide produced 20.2% average weight loss at 72 weeks. Semaglutide produced 13.7%. That is a 47% greater relative reduction — not a marginal statistical difference, but a clinically meaningful one. And it confirmed what many of us had been observing in practice for the past two years.
That said, this comparison is not as simple as “tirzepatide wins, use tirzepatide.” The full picture is more nuanced, and I want to give you an honest account of both what the data shows and what I actually see in our clinics.
What the clinical trial data shows
Weight loss — SURMOUNT-5
SURMOUNT-5 enrolled 751 adults with obesity but without type 2 diabetes and assigned them to the maximum tolerated dose of either tirzepatide (10 mg or 15 mg) or semaglutide (1.7 mg or 2.4 mg) for 72 weeks. Key results:
- Mean weight loss: 20.2% with tirzepatide vs. 13.7% with semaglutide
- In absolute terms: approximately 50 lbs with tirzepatide vs. 33 lbs with semaglutide
- Waist circumference reduction: 18.4 cm vs. 13.0 cm
- 1 in 3 tirzepatide patients achieved ≥25% body weight loss, vs. 1 in 6 on semaglutide (31.6% vs. 16.1%)
- Tirzepatide was superior on all five key secondary endpoints
A post-hoc cardiovascular analysis published in European Heart Journal Open (September 2025) found tirzepatide was also associated with a greater predicted 10-year cardiovascular risk reduction — an absolute reduction of 2.4% vs. 1.4% with semaglutide.
Important context: SURMOUNT-5 was an open-label trial funded by Eli Lilly, the manufacturer of tirzepatide. Participants and investigators knew which drug was being administered. This does not invalidate the results — they were published in the most rigorous peer-reviewed journal in medicine — but it is standard practice to disclose. Both medications remain highly effective, and semaglutide has a larger long-term cardiovascular outcomes dataset via the SELECT trial.
Side effects — what the trial data shows
Both medications cause gastrointestinal side effects. What SURMOUNT-5 revealed is a meaningful difference in how often those side effects cause patients to stop treatment: GI-related discontinuation was 2.7% with tirzepatide vs. 5.6% with semaglutide — roughly twice the rate of treatment-ending side effects with semaglutide. A separate meta-analysis found semaglutide was also associated with a significantly higher risk of gallbladder-related disorders compared to tirzepatide.
What I actually see in our clinics
The super responders
The most striking thing I see on both medications is not the average — it’s the super responders. Patients who lose 80, 90, 100 pounds or more. They exist on both semaglutide and tirzepatide. I’ve seen it enough times that I no longer think of these as outliers. We don’t have a reliable way to predict who they’ll be in advance, which is part of why the evaluation and monitoring process matters so much. You find out when you start treating.
Super responders seem more common on tirzepatide, and the magnitude tends to be larger. But semaglutide produces them too — and for a patient who responds that well, there’s no clinical reason to switch.
Speed of response
Tirzepatide patients lose weight noticeably faster in the first four to eight weeks. The dual GIP/GLP-1 action produces stronger and earlier appetite suppression for most patients. Early response is one of the strongest predictors of long-term success on GLP-1 therapy — patients who see results in the first month stay engaged and stay on treatment.
Semaglutide patients often have a slower start, particularly at the initiation dose. Some providers and patients interpret this as the medication “not working” — but it’s usually just the pharmacology. Appetite suppression comes on more gradually.
Plateaus
Plateaus are one of the most common reasons patients become discouraged and discontinue treatment. In my experience, tirzepatide patients hit plateau less frequently and later in their treatment course than semaglutide patients. When they do plateau, the dose escalation ceiling is higher, and the clinical flexibility of vial-based delivery means we can make smaller adjustments than pen devices allow. For more on how that works in practice, see our GLP-1 microdosing guide.
The GI side effect difference
The distinction I observe goes beyond how often patients stop treatment. The character of the GI side effects differs between the two medications. Semaglutide tends to produce nausea and constipation — most pronounced in the first few weeks of each dose escalation, though for some patients it never fully resolves. Tirzepatide more commonly causes loose stools or diarrhea rather than nausea. This makes physiological sense: semaglutide’s stronger effect on gastric emptying delay favors constipation; tirzepatide’s GIP component affects gut motility differently. For most patients, the diarrhea is manageable and transient — and many actually prefer it to nausea.
One of the most consistent patterns I see is patients who come to us specifically because they couldn’t tolerate semaglutide elsewhere — typically due to nausea. When we switch them to tirzepatide, the nausea resolves almost entirely. These are two distinct molecular mechanisms, not just dose variations of the same drug. That’s exactly why the switch can work.
Who I still start on semaglutide
Tirzepatide is not always my first recommendation, and cost is a real factor. Compounded semaglutide at Rivas starts at $115 per week. Compounded tirzepatide starts at $165 per week. That’s a $50/week difference, or $200/month. For many patients, that’s meaningful — particularly early in treatment when they’re still determining whether GLP-1 therapy will work for them.
Beyond cost, some patients tolerate semaglutide exceptionally well. If someone loses weight steadily with minimal side effects on semaglutide, I have no clinical reason to push them toward tirzepatide.
My general framework:
- Start with semaglutide if cost is a significant concern, or if there is no strong reason to expect poor tolerance
- Start with tirzepatide if the patient has tried semaglutide before and struggled with side effects, if faster initial response matters clinically, or if the patient’s goals require larger total weight loss
- Switch to tirzepatide if a patient on semaglutide is experiencing persistent nausea or has plateaued and escalation options are limited
One pattern worth noting: men
I see a consistent pattern with male patients who struggle to tolerate semaglutide — nausea and GI disruption can be particularly disruptive for them, and they’re often less willing to push through it. Tirzepatide tends to be better tolerated in this group. SURMOUNT-5 also noted that weight loss was approximately 6% lower in men than women in both treatment groups — but men on tirzepatide still do very well in absolute terms.
Not sure which is right for you?
Your provider evaluates your history and goals at your first visit — and can start treatment the same day.
Book a Visit →What about higher-dose semaglutide?
In April 2026, the FDA approved semaglutide 7.2 mg (Wegovy HD) under an accelerated review process. The STEP UP trial, published in The Lancet Diabetes & Endocrinology in September 2025, showed 18.7% average weight loss at 72 weeks compared to 15.6% at the standard 2.4 mg dose. Nearly a third of patients achieved ≥25% weight loss.
This matters because it narrows the gap with tirzepatide considerably. At 7.2 mg, semaglutide produces 18.7% vs. tirzepatide’s 20.2% — a difference of about 1.5 percentage points, versus the 6.5-point gap at standard doses. For patients who have been doing well on semaglutide but haven’t hit their goals, this is now a meaningful escalation option before switching drug classes entirely.
However, 7.2 mg introduces a side effect that doesn’t exist at standard doses: dysesthesia — abnormal skin sensations described as burning, hypersensitivity, or pain. This occurred in 22.9% of patients at 7.2 mg versus 6% at 2.4 mg and 0.5% on placebo. The FDA is actively investigating this signal. Most cases resolved spontaneously or with dose reduction, but it is a new and notable adverse effect that does not appear with tirzepatide. The drug is also just launching — supply and availability are uncertain in early 2026.
My take: Wegovy HD is a legitimate escalation option for patients established on standard-dose semaglutide who want to push further without switching medications. For patients starting fresh, or switching from semaglutide for efficacy reasons, tirzepatide remains the more proven option at comparable weight loss levels — without the dysesthesia risk.
A side-by-side comparison
| Factor | Semaglutide (Wegovy 2.4 mg) | Tirzepatide (Zepbound) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 receptor agonist |
| Avg. weight loss (SURMOUNT-5) | 13.7% / ~33 lbs at 72 weeks | 20.2% / ~50 lbs at 72 weeks |
| Speed of response | Gradual — builds over weeks | Faster early response |
| GI side effect profile | Nausea and constipation more common | Diarrhea more common; nausea much less common |
| GI discontinuation rate | 5.6% (SURMOUNT-5) | 2.7% (SURMOUNT-5) |
| Plateaus | More common earlier in treatment | Less frequent, tends to occur later |
| Cardiovascular outcomes | SELECT trial completed — 20% reduction in MACE | SURMOUNT-MMO ongoing; favorable intermediate data |
| Sleep apnea approval | Not indicated | FDA-approved for moderate-to-severe OSA (Dec 2024) |
| Higher-dose option | Wegovy HD 7.2 mg — FDA approved April 2026; 18.7% avg weight loss; new dysesthesia signal (22.9%) | No intraclass escalation — 15 mg is the ceiling |
| Starting cost at Rivas | $115/week (visit + medication) | $165/week (visit + medication) |
| Best suited for | Cost-conscious patients; those who tolerate it well; patients with established cardiovascular disease where SELECT data matters | Patients seeking maximum weight loss; those who struggled with semaglutide side effects; patients with OSA; men with poor GI tolerance |
What about patients who don’t respond to either drug?
I want to address this directly because it comes up in practice and I haven’t seen it discussed honestly in most comparison articles.
I see patients who fail to respond meaningfully to semaglutide — even at 1 mg and above, with good adherence — and when we switch them to tirzepatide, they still don’t respond. Not a poor response. A genuinely flat response. The scale doesn’t move the way it does for almost everyone else on either drug.
Emerging research now suggests a third explanation that clinicians rarely discuss: some patients may have receptor-level biology that limits their response to this entire drug class. A large-scale genome-wide association study published in Nature in April 2026, conducted by 23andMe researchers using data from 27,885 GLP-1 medication users, identified a specific variant in the GLP1R gene — the gene that encodes the primary receptor these drugs target — associated with differential weight loss efficacy. Because both semaglutide and tirzepatide share GLP-1 receptor activation as a core mechanism, a patient with suboptimal GLP1R receptor function may have a biological ceiling that neither drug can push past regardless of dose.
This does not mean non-responders should give up. It means the mechanism isn’t working as expected, and the clinical question shifts: is the dose truly optimized? Is there another metabolic factor at play? Is bariatric surgery a more appropriate conversation? But it does provide a framework for understanding why some patients — despite doing everything right — don’t get the results the trials would predict.
If you have tried semaglutide at meaningful doses for 12+ weeks with minimal response, switching to tirzepatide is still worth attempting. But if you show a flat response to tirzepatide as well, that is worth a direct conversation with your provider about whether GLP-1 therapy is the right primary approach for you.
Could genetic testing tell you which drug will work for you?
This is a question I’m asked increasingly, and the honest answer as of mid-2026 is: not yet in clinical form — but the science just arrived and it’s more interesting than most people realize.
The same April 2026 Nature study identified two specific genetic variants with meaningful implications.
GLP1R rs10305420 — efficacy predictor. A missense variant in the GLP-1 receptor gene is associated with approximately 0.76 kg of additional weight loss per copy of the effect allele. The effect is modest at the individual level but statistically robust across nearly 28,000 patients and replicated in an independent NIH All of Us cohort. This is the first direct genetic evidence that variation in the drug’s target gene contributes to why some people respond dramatically and others barely move.
GIPR rs1800437 — tirzepatide-specific nausea predictor. A variant in the GIP receptor gene was associated with significantly higher odds of nausea and vomiting — but only in patients taking tirzepatide, not semaglutide. Carriers of this variant were 83% more likely to experience vomiting on tirzepatide. Because semaglutide does not act on the GIP receptor at all, this variant had no effect on semaglutide tolerability whatsoever. The lead researcher described the signal as “very, very clean.” This means there may be patients who would tolerate semaglutide well but experience significant nausea on tirzepatide — and right now, the only way to discover that is to try the medication.
23andMe has already released a consumer-facing GLP-1 response report through its Total Health service based on these findings. But a validated clinical diagnostic test does not yet exist. The models combining genetic and non-genetic factors explained only about 25% of the variance in weight loss outcomes. Genetics is a piece of the picture, not the whole story. My expectation is that within the next three to five years, pharmacogenomic testing for GLP-1 response will become part of clinical practice. We are watching this space closely.
What’s coming next: retatrutide
No comparison of this drug class would be complete without mentioning retatrutide — a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. It is not yet FDA approved, but Phase 3 data from the TRIUMPH-4 trial (December 2025) showed an average of 28.7% body weight loss at 68 weeks at the 12 mg dose — the highest ever recorded in a pharmacological weight loss trial.
The clinical story worth understanding: some participants discontinued treatment because of perceived excessive weight loss. Lilly explicitly cited this in their TRIUMPH-4 reporting. Eight patients in the Phase 2 trial required protocol-driven dose reductions because their BMI dropped below 22. Discontinuation rates of 12–18% at the highest doses were partially attributed to patients losing more weight than was clinically appropriate for their starting BMI.
This is a genuinely novel clinical phenomenon. We have never had a weight loss drug powerful enough to require stopping because it worked too well. Retatrutide also produced a dysesthesia signal (8.8–20.9% at Phase 3 doses) — the same new side effect now appearing with high-dose semaglutide, and its emergence in two separate next-generation drugs is a pattern worth watching.
FDA filing for retatrutide was expected from Lilly in late 2025. If approved, it would represent a significant step above what tirzepatide currently offers — particularly for patients with very high starting BMIs or those who have plateaued at maximum tirzepatide doses. We will be evaluating it for the Rivas program as the approval process progresses.
Both are available at Rivas
We offer both compounded semaglutide and compounded tirzepatide across all 15 of our Maryland and Virginia locations, as well as brand-name Wegovy and Zepbound when clinically appropriate. Comparing the two brand-name options? Use our side-by-side Wegovy vs. Zepbound calculator → | See current pricing →
At your first visit, your provider reviews your health history, goals, prior medication experience, and relevant clinical factors — and makes a recommendation. In most cases we can start treatment the same day. Use the GLP-1 dose calculator if you want to understand unit conversions for compounded vials before your visit.
Frequently Asked Questions
In the SURMOUNT-5 head-to-head trial (N Engl J Med, May 2025), tirzepatide produced 20.2% average weight loss compared to 13.7% with semaglutide over 72 weeks — a 47% greater relative reduction. Tirzepatide was superior on all five key secondary endpoints. “More effective” is a simplification, but tirzepatide does produce larger average weight loss for most patients. Both remain highly effective options, and the right choice depends on individual factors your provider evaluates.
Both cause gastrointestinal side effects, but the profile differs. Semaglutide more commonly causes nausea and constipation. Tirzepatide more commonly causes loose stools or diarrhea, with nausea being much less common. Patients on tirzepatide are about half as likely to stop treatment due to side effects compared to semaglutide (2.7% vs. 5.6% in SURMOUNT-5). Patients who switch from semaglutide to tirzepatide due to nausea typically see significant improvement. Learn more about the side effects of Zepbound.
Yes. If you are experiencing side effects on semaglutide, have plateaued, or want to discuss whether tirzepatide might produce better results, your Rivas provider can discuss transitioning at any visit. The two medications have distinct mechanisms — tolerance of one does not predict tolerance of the other.
A flat response to both medications despite adequate dosing and adherence is uncommon but real. Research published in Nature in April 2026 identified a variant in the GLP1R gene associated with reduced efficacy across GLP-1 medications. Since both drugs activate the GLP-1 receptor, patients with less favorable variants in this gene may have a biological ceiling that limits response to the entire class. If you have not responded to meaningful doses of both medications, this is worth a direct conversation with your provider about whether GLP-1 therapy is the right primary approach.
Not yet in validated clinical form. A large study published in Nature in April 2026 identified specific variants in the GLP1R and GIPR genes that predict differential weight loss and side effect risk on GLP-1 medications. 23andMe has released a consumer report based on these findings. However, no clinical diagnostic test currently exists that would meaningfully guide prescribing decisions. Expect this to change over the next few years.
Both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is FDA-approved for weight management and obstructive sleep apnea. The molecule is the same — the difference is indication, labeling, and insurance coverage pathways.
Both contain semaglutide. Ozempic is approved for type 2 diabetes; Wegovy is approved for weight management at a higher maximum dose. The molecule is the same — the difference is indication, dosing ceiling, and pen formats.
At Rivas, compounded semaglutide starts at $115/week and compounded tirzepatide starts at $165/week. Both prices include your provider visit and medication — there is no separate pharmacy bill. See full pricing →
In our clinical experience, yes — most tirzepatide patients notice appetite suppression within the first one to two weeks, and early weight loss tends to be faster. The trial data supports this. Both medications require several weeks to reach full therapeutic effect at any given dose.
Ready to find out which is right for you?
Book your first visit at any Rivas location. Your provider evaluates your history, discusses both options, and — if appropriate — can start treatment the same day.
Book Your First Visit →15 locations in MD & VA · From $115/week · Medication included
References
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26–36.
- Auton A, et al. Genetic predictors of GLP1 receptor agonist weight loss and side effects. Nature. April 2026. doi:10.1038/s41586-026-10330-z
- Wharton S, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP). Lancet Diabetes Endocrinol. 2025.
- Lingvay I, et al. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D). Lancet Diabetes Endocrinol. 2025.
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526.
- Lilly. TRIUMPH-4 Phase 3 trial topline results. Press release. December 2025.
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221–2232.
- Mamas MA, et al. Tirzepatide vs. semaglutide and 10-year cardiovascular risk reduction: post-hoc analysis of SURMOUNT-5. Eur Heart J Open. 2025;5(5):oeaf117.
- Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(13):1193–1205.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.
- Wadden TA, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 5). N Engl J Med. 2021;384(11):989–1002.
This article reflects the clinical perspective of Eli Luft, PA-C, based on his experience treating patients at Rivas Medical Weight Loss primarily using compounded GLP-1 medications. It is for educational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved. All treatment decisions are made by a licensed provider following an individualized medical evaluation. Individual results vary.
